Evidence map›Paper›PMID 22926961›Full record

ArticleJournal of the American Society for Mass Spectrometry2012

The use of MALDI-TOF-MS and in silico studies for determination of antimicrobial peptides' affinity to bacterial cells.

Santi M Mandal, Ludovico Migliolo, Octavio L Franco

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Santi M MandalMass Spectrometry and Proteomics Laboratory Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur, WB, India.
Ludovico Migliolo
Octavio L Franco
Indian Institute of Technology Kharagpur · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several methods have been proposed for determining the binding affinity of antimicrobial peptides (AMPs) to bacterial cells. Here the utilization of MALDI-TOF-MS was proposed as a reliable and efficient method for high throughput AMP screening. The major advantage of the technique consists of finding AMPs that are selective and specific to a wide range of Gram-negative and -positive bacteria, providing a simple reliable screening tool to determine the potential candidates for broad spectrum antimicrobial drugs. As a prototype, amp-1 and -2 were used, showing highest activity toward Gram-negative and -positive membranes respectively. In addition, in silico molecular docking studies with both peptides were carried out for the membranes. In silico results indicated that both peptides presented affinity for DPPG and DPPE phospholipids, constructed in order to emulate an in vivo membrane bilayer. As a result, amp-1 showed a higher complementary surface for Gram-negative while amp-2 showed higher affinity to Gram-positive membranes, corroborating MS analyses. In summary, results here obtained suggested that in vitro methodology using MALDI-TOF-MS in addition to theoretical studies may be able to improve AMP screening quality.

Indexed as

Antimicrobial Cationic PeptidesComputer SimulationEscherichia coliHydrogen BondingHydrophobic and Hydrophilic InteractionsLipid BilayersModels, MolecularPhosphatidylethanolaminesPhosphatidylglycerolsProtein BindingSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStaphylococcus epidermidisAntimicrobial Cationic PeptidesLipid BilayersphosphatidylethanolaminePhosphatidylethanolaminesPhosphatidylglycerols

Identifiers

PMID22926961
OpenAlexW2000533064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.